Nashaat Turkman

Dr. Nashaat Turkman

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
NTNashaat Turkman
Nashaat Turkman
DLDaxing Liu
Daxing Liu
IPIsabella Pirola
Isabella Pirola
Herein, we describe the design, synthesis and deciphering of the key characteristics of the structure activity relationship (SAR) of trifluoromethyloxadiazole (TFMO) bearing class-IIa HDAC inhibitors. Our medicinal chemistry campaign of 23 compounds identified compound 1 as a highly potent inhibitor with sub nM affinity to class-IIa HDAC4 isoform. Therefore, We radiolabeled compound 1 (named thereafter as NT160) with [18F]fluoride thus producing the identical [18F]-NT160 as a diagnostic tool for positron emission tomography (PET). [18F]-NT160 was produced in high radiochemical purity (>95%), moderate radiochemical yield (2−5%) and moderate molar activity in the range of 0.30−0.85 GBq/umol (8.0−23.0 mCi/umol). We also established that [18F]-NT160 can cross the blood brain barrier and bind to class-IIa HDACs in vivo. The combination of [18F]-NT160 and 1 represent a novel theranostic pair using the same molecule to enable diagnostic PET imaging with [18F]-NT160 followed by targeted therapy with NT160.

1 November 2010 in Journal of Labelled Compounds and Radiopharmaceuticals
Verified
Journal Article
Closed access
PDF file
NTNashaat Turkman
Nashaat Turkman
JGJuri G. George Gelovani
Juri G. George Gelovani
MAMian Alauddin
Mian Alauddin

21 May 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NTNashaat Turkman
Nashaat Turkman
DLDaxing Liu
Daxing Liu
IPIsabella Pirola
Isabella Pirola
Small molecules that contain the (TFMO) moiety were reported to specifically inhibit the class-IIa histone deacetylases (HDACs), an important target in cancer and the disorders of the central nervous system (CNS). However, radiolabeling methods to incorporate the [18F]fluoride into the TFMO moiety are lacking. Herein, we report a novel late-stage incorporation of [18F]fluoride into the TFMO moiety in a single radiochemical step. In this approach the bromodifluoromethyl-1,2,4-oxadiazole was converted into [18F]TFMO via no-carrier-added bromine-[18F]fluoride exchange in a single step, thus producing the PET tracers with acceptable radiochemical yield (3–5%), high radiochemical purity (> 98%) and moderate molar activity of 0.33–0.49 GBq/umol (8.9–13.4 mCi/umol). We validated the utility of the novel radiochemical design by the radiosynthesis of [18F]TMP195, which is a known TFMO containing potent inhibitor of class-IIa HDACs.

22 June 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DLDaxing Liu
Daxing Liu
JCJules Cohen
Jules Cohen
NTNashaat Turkman
Nashaat Turkman
Given our interest in the utility of liposomes for molecular imaging and theranostics, we investigated how coating the outer layer of the liposome affects internalization by breast cancer cell lines in vitro and in breast tumor tissues in vivo. Indeed, we discovered that a remarkably high liposomal uptake can be achieved by DBCO (dibenzocyclooctyne) soft coating. Our data demonstrates that decorating the terminal lipid with a DBCO moiety at a specific density induces increased tumor uptake in vivo (tumor uptake ~ 50%) compared to conventional undecorated liposome (tumor uptake ~ 20%). In this study, we report improved visualization of breast cancer cells in vivo using a 4T1 orthotopic breast cancer model and primary breast tumor xenograft models MDA-MB-231 and MDA-MB-436. L-PEG2000-DBCO coated liposomes demonstrate increased accumulation in breast cancer cells independent of tumor size, type, position, receptor expression, as well as the condition of the host mice. We expect these findings to have a major positive impact on the practical utility of liposomes in image-guided applications and precision medicine theranostics.

27 July 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RBRobin Bonomi
Robin Bonomi
VPVadim Popov
Vadim Popov
MLMaxwell T. Laws
Maxwell T. Laws
DGDavid Gelovani
David Gelovani
AMAnjoy Majhi
Anjoy Majhi
JGJuri G. George Gelovani
Juri G. George Gelovani

17 April 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
NTNashaat Turkman
Nashaat Turkman
SXSulan Xu
Sulan Xu
CHChun-Han Huang
Chun-Han Huang
CEChristopher Eyermann
Christopher Eyermann
JSJulia Salino
Julia Salino
PKPalwasha Khan
Palwasha Khan
We utilized positron emission tomography (PET) imaging in vivo to map the spatiotemporal biodistribution/expression of class-IIa histone deacetylases (class-IIa HDACs) in the central nervous system (CNS). Herein we report an improved radiosynthesis of [18F]NT160 using 4-hydroxy-TEMPO which led to a significant improvement in radiochemical yield and molar activity. PET imaging with [18F]NT160, a highly potent class-IIa HDAC inhibitor, led to high-quality and high-contrast images of the brain. [18F]NT160 displayed excellent pharmacokinetic and imaging characteristics: brain uptake is high in gray matter regions, tissue kinetics are appropriate for a 18F-tracer, and specific binding for class-IIa HDACs is demonstrated by self-blockade. Higher uptake with [18F]NT160 was observed in the hippocampus, thalamus, and cortex while the uptake in the cerebellum was relatively low. Overall, our current studies with [18F]NT160 will likely facilitate the development and clinical translation of PET tracers for imaging of class-IIa HDACs biodistribution/expression in cancer and the CNS.